JPH08225446A - 血清コレステロールを低下させるための方法 - Google Patents

血清コレステロールを低下させるための方法

Info

Publication number
JPH08225446A
JPH08225446A JP7299787A JP29978795A JPH08225446A JP H08225446 A JPH08225446 A JP H08225446A JP 7299787 A JP7299787 A JP 7299787A JP 29978795 A JP29978795 A JP 29978795A JP H08225446 A JPH08225446 A JP H08225446A
Authority
JP
Japan
Prior art keywords
substituted
hydrogen
formula
ring
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP7299787A
Other languages
English (en)
Japanese (ja)
Inventor
Timothy A Grese
ティモシー・アラン・グリース
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of JPH08225446A publication Critical patent/JPH08225446A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
JP7299787A 1994-11-18 1995-11-17 血清コレステロールを低下させるための方法 Withdrawn JPH08225446A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/342,181 US5446071A (en) 1994-11-18 1994-11-18 Methods for lowering serum cholesterol
US342181 1994-11-18

Publications (1)

Publication Number Publication Date
JPH08225446A true JPH08225446A (ja) 1996-09-03

Family

ID=23340722

Family Applications (1)

Application Number Title Priority Date Filing Date
JP7299787A Withdrawn JPH08225446A (ja) 1994-11-18 1995-11-17 血清コレステロールを低下させるための方法

Country Status (4)

Country Link
US (1) US5446071A (cg-RX-API-DMAC10.html)
EP (1) EP0712627A2 (cg-RX-API-DMAC10.html)
JP (1) JPH08225446A (cg-RX-API-DMAC10.html)
CA (1) CA2163156A1 (cg-RX-API-DMAC10.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
SK9592002A3 (en) * 2000-01-28 2003-12-02 Endorech Inc A method for reduction or elimination of the incidence of menopausal symptoms, method of treatment or decreasing the risk of an acquiring disease, a pharmaceutical composition and a kit
EP1838296B1 (en) * 2004-10-20 2012-08-08 Resverlogix Corp. Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
EP2314295B1 (en) 2005-07-29 2015-01-28 Resverlogix, Inc Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
CN101641339B (zh) * 2007-02-01 2013-07-17 雷斯韦洛吉克斯公司 用于预防和治疗心血管疾病的化合物
KR101629356B1 (ko) 2008-06-26 2016-06-13 리스버로직스 코퍼레이션 퀴나졸리논 유도체의 제조방법
US8952021B2 (en) 2009-01-08 2015-02-10 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
AU2010224523B2 (en) 2009-03-18 2014-05-08 Resverlogix Corp. Novel anti-inflammatory agents
MX374414B (es) 2009-04-22 2025-03-06 Resverlogix Corp Nuevos agentes anti-inflamatorios.
EP2580210B1 (en) 2010-06-10 2017-03-01 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
SI2773354T1 (sl) 2011-11-01 2019-08-30 Resverlogix Corp. Peroralne formulacije s takojšnjim sproščanjem za substituirane kinazolinone
EP2791132A4 (en) 2011-12-14 2015-08-05 Seragon Pharmaceuticals Inc ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
AP2014007657A0 (en) 2011-12-16 2014-05-31 Olema Pharmaceuticals Inc Novel benzopyran compounds, compositions and uses thereof
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
CN105073744B (zh) 2012-12-21 2019-11-08 齐尼思表观遗传学有限公司 作为溴结构域抑制剂的新型杂环化合物
CN107530356A (zh) 2015-03-13 2018-01-02 雷斯韦洛吉克斯公司 用于治疗补体相关疾病之组合物及治疗方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274213A (en) * 1961-09-05 1966-09-20 Upjohn Co Alkoxy-substituted 2-phenyl-1-(tertiary-aminoalkoxy)phenyl-3, 4-dihydronaphthalenes
US3313853A (en) * 1963-10-16 1967-04-11 Upjohn Co 2-(tertiaryaminoalkoxyphenyl)-3, 4-dihydronaphthalenes and 2-(tertiaryaminoalkoxyphenyl) -3, 4- dihydro -1(2h)-naphthalenones
DE1543749A1 (de) * 1966-02-16 1969-12-11 Merck Ag E Verfahren zur Herstellung von 3,4-cis-4-Aryl-isoflavanen
US3597431A (en) * 1969-07-23 1971-08-03 American Cyanamid Co 1-(4'-substituted-phenyl)-2-(phenyl lower alkyl)-1,2,3,4-tetrahydroisoquinolines
US3961062A (en) * 1973-03-26 1976-06-01 Hoechst Aktiengesellschaft Pharmaceutical composition containing 1-(imidazole-1-yl)-isoquinolines and method of treating hyperlipemia
DE2314985A1 (de) * 1973-03-26 1974-10-17 Hoechst Ag 1-(imidazol-1-yl)-isochinoline und verfahren zu ihrer herstellung
US3870722A (en) * 1973-11-02 1975-03-11 Sandoz Ag 2-Methyl-3-substituted-4-aryl isoquinolines
US4447662A (en) * 1982-06-10 1984-05-08 Air Products And Chemicals, Inc. Beta-dicarbonyl compounds for the promotion of aromatic nitration by nitrogen tetroxide
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
US5362878A (en) * 1991-03-21 1994-11-08 Pfizer Inc. Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT)
US5446061A (en) * 1993-11-05 1995-08-29 Eli Lilly And Company Methods for lowering serum cholesterol

Also Published As

Publication number Publication date
EP0712627A2 (en) 1996-05-22
EP0712627A3 (cg-RX-API-DMAC10.html) 1996-06-26
US5446071A (en) 1995-08-29
CA2163156A1 (en) 1996-05-19

Similar Documents

Publication Publication Date Title
JPH08225446A (ja) 血清コレステロールを低下させるための方法
JP3197129B2 (ja) ベンゾチオフェン類を含有する医薬組成物
KR0161300B1 (ko) 뼈 손실 예방에 유용한 벤조티오펜
PT652005E (pt) Metodo para inibicao da endometriose
JPH07215859A (ja) 月経時の症状の治療法およびそれに用いる組成物
JPH07304660A (ja) １，１，２−トリフェニルブタ−１−エン誘導体を用いる大動脈平滑筋細胞の増殖及び再狭窄の抑制法
EP0652001A1 (en) Methods for treating per-menopausal syndrome
US5691355A (en) Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs
JPH07215856A (ja) 肺高血圧性疾患を抑制するための医薬組成物
JPH07215855A (ja) 自己免疫疾患を抑制する方法
JPH09315962A (ja) テストステロンを増加させる方法
JPH10504572A (ja) ウイルスの複製を阻害する方法
JPH07196500A (ja) 閉経期後症候群に関連する血管運動症状および併発性心理的障害を抑制するための医薬組成物
JPH07215871A (ja) 血清コレステロールを減少させるための方法
US5426123A (en) Method for lowering serum cholesterol with 1,1,2-triphenylbut-1-ene derivatives
JPH07196498A (ja) Ｌｄｌの酸化およびアテローム性動脈硬化症を防ぐための医薬組成物
HU220607B1 (hu) Benzotiofénszármazékok alkalmazása angiogenezis és érképző betegségek gátlására alkalmas gyógyszerkészítmények előállítására
JPH07215858A (ja) 機能障害性子宮出血を抑制する方法
JPH07242546A (ja) ミエロペルオキシダーゼ活性の阻害に適した医薬組成物
JPH07196502A (ja) 閉経期後の女性におけるｃｎｓ障害を抑制するための医薬組成物
JPH07196501A (ja) 胸部疾患を抑制するための医薬組成物
JP2001523676A (ja) エストロゲン欠乏症候群の治療に有用な２−アリールベンゾ［ｂ］チオフェン
JPH07196492A (ja) 体重増加を抑制する、または体重減少を誘発するための医薬組成物
JPH08225445A (ja) 骨損失を抑制する方法
KR19980701589A (ko) 환경 에스트로겐의 억제 방법(Methods of Inhibiting Environmental Estrogens)

Legal Events

Date Code Title Description
A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20030204